Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001448.
    PubMed     Text format     Abstract available


  2. PRICE H, Dunn D, Zachary T, Vudriko T, et al
    Hepatitis B serological markers and plasma DNA concentrations: baseline results from the DART trial.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001454.
    PubMed     Text format     Abstract available


  3. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    HCV drives increased type I IFN-associated impairments associated to fibrosis severity in ART-treated HIV-1-HCV coinfected individuals.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001455.
    PubMed     Text format     Abstract available


  4. TOBIN SC
    Evaluating the generalizability of clinical trials of direct-acting antivirals for HIV/HCV-coinfection.
    AIDS. 2017 Mar 1. doi: 10.1097/QAD.0000000000001439.
    PubMed     Text format    


    January 2017
  5. REID M, Ma Y, Scherzer R, Price JC, et al
    Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
    AIDS. 2017;31:385-393.
    PubMed     Text format     Abstract available


  6. SORIANO V, Sherman KE, Barreiro P
    Hepatitis Delta and HIV Infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001424.
    PubMed     Text format     Abstract available


  7. PINATO DJ, Pria AD, Sharma R, Bower M, et al
    Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV co-infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001422.
    PubMed     Text format     Abstract available


  8. SEREMBA E, Ssempijja V, Kalibbala S, Gray RH, et al
    Hepatitis B incidence and prevention with antiretroviral therapy among HIV positive individuals in Rakai, Uganda.
    AIDS. 2017 Jan 17. doi: 10.1097/QAD.0000000000001399.
    PubMed     Text format     Abstract available



  9. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe.
    AIDS. 2017;31:127-135.
    PubMed     Text format     Abstract available


  10. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Text format     Abstract available


    December 2016
  11. PETERS L, Cozzi-Lepri A
    Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?
    AIDS. 2016 Dec 21. doi: 10.1097/QAD.0000000000001378.
    PubMed     Text format     Abstract available


  12. MERCHANTE N, Rivero-Juarez A, Tellez F, Merino D, et al
    Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    October 2016
  13. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.
    AIDS. 2016;30:2469-2476.
    PubMed     Text format     Abstract available


    September 2016
  14. SCHERZER R, Heymsfield SB, Rimland D, Powderly WG, et al
    Association of serum albumin and AST with 5-year all-cause mortality in HIV/HCV coinfection and HIV monoinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  15. THORNE C, Turkova A, Indolfi G, Venturini E, et al
    Co-infection with HIV and HCV in 229 children and young adults living in Europe.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  16. NEWSUM AM, Ho CK, Lieveld FI, Van De Laar TJ, et al
    The hepatitis C virus NS3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    August 2016
  17. MILLARD JD, Henry J, Rizvi SS, Nelson M, et al
    Direct-acting antivirals for acute hepatitis C in HIV-infected MSM.
    AIDS. 2016;30:2137-9.
    PubMed     Text format    


  18. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  19. GOWDA C, Brown TT, Compher C, Forde KA, et al
    Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    July 2016
  20. CACHAY E, Soriano V
    Is HIV still a special population for the treatment of hepatitis C?
    AIDS. 2016;30:2001-3.
    PubMed     Text format    


  21. CHEW KW, Bhattacharya D
    Virologic and immunologic aspects of HIV-HCV coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    June 2016
  22. HAGAN H, Jordan AE, Cleland CM
    Response to the calculation of population attributable fractions of risk factors for hepatitis C transmission: authors' reply.
    AIDS. 2016;30:1685.
    PubMed     Text format    


  23. SCHMIDT AJ, Bremer V
    Response to the calculation of population attributable fractions (PAFs) of risk factors for hepatitis C transmission.
    AIDS. 2016;30:1683-4.
    PubMed     Text format    


  24. SMOLDERS EJ, Kanter CT, Grintjes K, D'Avolio A, et al
    Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
    AIDS. 2016;30:1491-3.
    PubMed     Text format    


  25. GARCIA M, Le Moal G, Godet C, Beraud G, et al
    First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS. 2016;30:1487-8.
    PubMed     Text format    


    May 2016
  26. KHELOUFI F, Bellissant E, Cotte L, Poizot-Martin I, et al
    eGFR but not SLC polymorphisms influences anemia in HIV-HCV co-infected patients treated with boceprevir- or telaprevir-based therapy (ANRS HC26 and HC27 Study).
    AIDS. 2016.
    PubMed     Text format     Abstract available


    April 2016
  27. GARCIA-ALVAREZ M, Berenguer J, Jimenez-Sousa MA, Vazquez-Moron S, et al
    Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients.
    AIDS. 2016;30:1069-1074.
    PubMed     Text format     Abstract available


    February 2016
  28. ROSSI C, Cox J, Cooper C, Martel-Laferriere V, et al
    Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV co-infected patients.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  29. CHILDS K, Taylor C, Dieterich D, Agarwal K, et al
    Directly acting antivirals (DAAs) for HCV arrive in HIV/HCV co-infected patients: from 'mind the gap' to 'where's the gap?'
    AIDS. 2016.
    PubMed     Text format    


    January 2016
  30. BEGUELIN C, Vazquez M, Moradpour D, Sahli R, et al
    Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
    AIDS. 2016;30:530-3.
    PubMed     Text format    


  31. JIMENEZ-SOUSA MA, Berenguer J, Garcia-Alvarez M, Gutierrez-Rivas M, et al
    Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients.
    AIDS. 2016;30:465-70.
    PubMed     Text format     Abstract available


  32. MANDORFER M, Schwabl P, Steiner S, Scheiner B, et al
    Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  33. GRANT JL, Hawkins C, Brooks H, Palella FJ Jr, et al
    Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    AIDS. 2016;30:93-8.
    PubMed     Text format     Abstract available


  34. TOWNSEND K, Petersen T, Gordon LA, Kohli A, et al
    Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
    AIDS. 2016;30:261-6.
    PubMed     Text format     Abstract available


  35. FAGIUOLI S, Puoti M, Rizzardini G
    Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders?
    AIDS. 2016;30:323-5.
    PubMed     Text format    


  36. PARK LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, et al
    Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.
    AIDS. 2016;30:273-91.
    PubMed     Text format     Abstract available


    December 2015
  37. LIU L, Nardo D, Li E
    CD4+ T-cell recovery with suppressive ART induced rapid sequence evolution in HCV envelope but not NS3.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    November 2015
  38. PETERS MG, Bacchetti P, Boylan R, French AL, et al
    Enhanced liver fibrosis marker as a non-invasive predictor of mortality in HIV/HCV-coinfected women from the women's Interagency HIV study.
    AIDS. 2015.
    PubMed     Text format     Abstract available


  39. HULLEGIE SJ, de Winter BC, Posthouwer D, Koopmans PP, et al
    Safety of rilpivirine and boceprevir co-administration in HIV-infected patients treated for acute hepatitis C virus infection.
    AIDS. 2015.
    PubMed     Text format    


  40. GOESER F, Glassner A, Kokordelis P, Wolter F, et al
    HIV mono-infection is associated with an impaired anti-HCV activity of NK cells.
    AIDS. 2015.
    PubMed     Text format     Abstract available


  41. BEDIMO R, Cutrell J, Zhang S, Drechsler H, et al
    Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    October 2015
  42. HARPER KN
    Effective but expensive hepatitis C treatment for patients with HIV.
    AIDS. 2015;29:N17.
    PubMed     Text format    


    September 2015
  43. PRINAPORI R, Ricci E, Menzaghi B, Borghi V, et al
    Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy.
    AIDS. 2015;29:2061-2.
    PubMed     Text format    


  44. ZUCMAN D, Sene T, Hillaire S, Kahn JE, et al
    Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
    AIDS. 2015;29:1903-4.
    PubMed     Text format    



  45. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    AIDS. 2015;29:1821-30.
    PubMed     Text format     Abstract available


  46. REAL LM, Herrero R, Rivero-Juarez A, Camacho A, et al
    IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
    AIDS. 2015;29:1895-7.
    PubMed     Text format     Abstract available


    August 2015
  47. MUMTAZ GR, Weiss HA, Vickerman P, Larke N, et al
    Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa.
    AIDS. 2015;29:1701-10.
    PubMed     Text format     Abstract available


  48. THOMAS XV, Grady BP, Van Der Meer JT, Ho CK, et al
    Genetic characterization of multiple hepatitis C virus infections following acute infection in HIV-infected MSM.
    AIDS. 2015.
    PubMed     Text format     Abstract available


  49. HAGAN H, Jordan AE, Neurer J, Cleland CM, et al
    Incidence of sexually transmitted hepatitis C virus infection in HIV-positive MSM: a systematic review and meta-analysis.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    July 2015
  50. ALEMAN J, van den Berk GE, Franssen EJ, de Fijter CW, et al
    Tenofovir disoproxil treatment for a HIV-hepatitis B virus coinfected patient undergoing peritoneal dialysis: which dose do we need?
    AIDS. 2015;29:1579-80.
    PubMed     Text format    


  51. ZAEGEL-FAUCHER O, Bregigeon S, Cano CE, Obry-Roguet V, et al
    Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    AIDS. 2015;29:1505-10.
    PubMed     Text format     Abstract available


  52. BOYD A, Gozlan J, Miailhes P, Lascoux-Combe C, et al
    Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    June 2015
  53. THIO CL, Smeaton L, Hollabaugh K, Saulynas M, et al
    Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    AIDS. 2015;29:1173-82.
    PubMed     Text format     Abstract available


  54. MAURIN G, Halgand B, Bruscella P, Fresquet J, et al
    Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
    AIDS. 2015;29:1025-33.
    PubMed     Text format     Abstract available


    November 2014
  55. BHATIA R, Murphy AB, Raper JL, Chamie G, et al
    Testosterone replace therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems.
    AIDS. 2014.
    PubMed     Text format     Abstract available


    July 2014
  56. LEEMING DJ, Anadol E, Schierwagen R, Karsdal MA, et al
    Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers.
    AIDS. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: